February 18, 2026
Terns Pharmaceuticals CEO Amy Burrows details a data-driven pivot from obesity to oncology, focusing on its best-in-class CML drug TERN-701.
February 11, 2026
NGene's Detylimagine, a non-viral gene therapy, offers a local "one-two punch" to bladder cancer, showing high response rates where BCG fails.
February 4, 2026
Adaptin Bio uses patient T cells to ferry biologics across the blood-brain barrier, creating a new treatment paradigm for glioblastoma.
January 28, 2026
Zara CEO Marc Tessier-Levine details their $1B+ AI-first strategy to make drug development an engineering discipline and tackle undruggable targets.
January 21, 2026
Amuto-Scientific's AI platform targets unique protein shapes in diseased cells, aiming to create safer, more effective drugs for cancer.
January 14, 2026
Nenology's particle engineering creates microparticles for intratumoral drug delivery, boosting cancer-killing efficacy while reducing toxicity.
January 7, 2026
Alt-Pep targets toxic alpha-sheet oligomers for early Alzheimer's detection and treatment, aiming to intervene decades before symptoms appear.
December 31, 2025
Biotech's 2025 boom saw M&A and stock surges. For 2026, focus shifts to FDA stability, deal flow, and navigating political headwinds.
December 24, 2025
Alley Therapeutics is tackling the opioid crisis with ATX-101, a 30-day dissolvable implant for post-surgical pain management.
December 17, 2025
Canary Speech uses AI to analyze vocal biomarkers—not what you say, but how you say it—to detect neurological and psychiatric diseases early.
December 10, 2025
Inflammatics' AI-driven Triverity test tackles sepsis by rapidly analyzing immune response, distinguishing infections and predicting severity.
December 3, 2025
Rion is pioneering regenerative medicine with platelet-derived exosomes, offering a scalable, cost-effective alternative to cell therapies.
November 19, 2025
Actuate Therapeutics' GSK3-beta inhibitor, Aeroglucib, shows promise by reversing chemoresistance and activating an anti-tumor immune response.
November 12, 2025
iZora applies a hub-and-spoke business model to ophthalmology, centralizing expertise to accelerate drug development and diversify risk.
November 5, 2025
OpenFold's Brian Weitzner on democratizing protein AI. Discover how this open-source tool rivals AlphaFold & accelerates drug design for all.
